The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer.
N. L. Berinstein
Consultant or Advisory Role - Immunovaccine
M. Morse
No relevant relationships to disclose
H. Kaufman
No relevant relationships to disclose
J. J. Nemunaitis
No relevant relationships to disclose
K. Odunsi
No relevant relationships to disclose
G. S. Chatta
No relevant relationships to disclose
G. Weir
Employment or Leadership Position - Immunovaccine
L. MacDonald
Employment or Leadership Position - Immunovaccine
M. Stanford
Employment or Leadership Position - Immunovaccine
M. Karkada
Employment or Leadership Position - Immunovaccine
R. Nigam
Employment or Leadership Position - Immunovaccine
M. Mansour
Employment or Leadership Position - Immunovaccine
Stock Ownership - Immunovaccine